RxDoctor Payments Data

Revati Shreeniwas

Pulmonary Disease · Stanford, CANPI 1538295704

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $725,600 of the $725,600 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Jazz Pharmaceuticals Inc.. Reporting peaked in 2023 at $472,800 and has fallen 94.4% since, to $26,600 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$725,600in general payments, 2019–2025

Across 31 payments — averaging $23,406 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$726K

What the payments were for

  • Consulting fees$725,600100%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Jazz Pharmaceuticals Inc.31$725,600

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$725,600 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Other pulmonary disease in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →